Perrigo Co PLC
PRGO
Company Profile
Business description
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm’s product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Contact
The Sharp Building
Hogan Place
DublinD02 TY74
IRLT: +353 17094000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
8,100
Stocks News & Analysis
stocks
Chart of the Week: BHP’s growth story faces a reality check
China’s slowing economy could weigh on BHP’s future growth.
stocks
3 best ASX growth stocks to buy for the long term
Here’s three high-quality growth companies with wide moats.
stocks
The ASX data center stock flying under the radar
While markets chase AI hype, this data centre company offers real data center earnings and a visible growth pipeline.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,009.90 | 3.10 | -0.03% |
| CAC 40 | 8,377.86 | 4.57 | -0.05% |
| DAX 40 | 24,915.49 | 84.04 | -0.34% |
| Dow JONES (US) | 52,552.97 | 105.67 | -0.20% |
| FTSE 100 | 10,572.24 | 56.32 | 0.54% |
| HKSE | 25,008.60 | 327.50 | 1.33% |
| NASDAQ | 25,881.95 | 387.28 | -1.47% |
| Nikkei 225 | 65,115.88 | 1,719.66 | -2.57% |
| NZX 50 Index | 13,655.19 | 40.41 | 0.30% |
| S&P 500 | 7,533.77 | 38.63 | -0.51% |
| S&P/ASX 200 | 8,816.10 | 0.70 | -0.01% |
| SSE Composite Index | 3,882.41 | 73.17 | -1.85% |